Ceppa F, Fontan E, Cremades S, Bihannic R, Bousquet A, Beauvillain L, Burnat P
Laboratoire de biochimie, toxicologie et pharmacologie cliniques, HIA Bégin, 69, avenue de Paris, 94163 Saint-Mandé cedex, France.
Rev Med Interne. 2007 Sep;28(9):594-602. doi: 10.1016/j.revmed.2007.03.005. Epub 2007 Apr 18.
Clinical implications associated with polymorphisms in drug-metabolizing genes involved in the chemotherapy of colorectal cancers (5-flurorouracil, oxaliplatin and irinotecan) are reviewed.
Treatments of colorectal cancers have been greatly improved last years but patients respond differently to identical medication. Genetic polymorphisms are one of the major causes of these individual responses to drugs associated with sometimes severe adverse effects. Pharmacogenetics is based on all polymorphisms that determine genetic human diversity associated with variable response to anticancer drugs.
Morbidity and mortality related to toxicity or inefficacy of these drugs could be reduced by analyzing the pharmacogenetic profile of patients before treatment. Results should be integrated in protocols for monitoring and assessment the dosage of drugs.
本文综述了与结直肠癌化疗（5-氟尿嘧啶、奥沙利铂和伊立替康）中药物代谢基因多态性相关的临床意义。
近年来，结直肠癌的治疗有了很大改善，但患者对相同药物的反应却各不相同。基因多态性是这些个体对药物反应不同的主要原因之一，有时还会导致严重的不良反应。药物遗传学基于所有决定人类遗传多样性的多态性，这些多态性与对抗癌药物的不同反应相关。
通过在治疗前分析患者的药物遗传学特征，可以降低与这些药物毒性或无效相关的发病率和死亡率。研究结果应纳入药物监测和剂量评估方案中。
